Amyloid Light-Chain Amyloidosis
Amyloid Light-Chain Amyloidosis (AL Amyloidosis) is a rare disease where abnormal proteins called amyloids build up in organs and tissues, potentially leading to organ damage and dysfunction.
AL Amyloidosis: Teclistamab Treatment Study
We are investigating whether teclistamab can improve blood health in patients with previously treated AL amyloidosis. This study will also look at the treatment's safety and its effects on quality of life.
What diseases are being studied?
Health conditions and diseases that the clinical trial is designed to study and treat.
Who can participate in the clinical trial?
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
- Are you 18 years old or older?
- Do you have AL amyloidosis (a type of protein buildup in the body)?
- Have you received at least one treatment for AL amyloidosis, such as Dara or bortezomib?
- Do you have symptoms affecting at least one organ, like your heart, kidneys, or nerves?
- Have you had any treatment for AL amyloidosis in the last 14 days?
Where is the clinical trial being conducted?
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Loading map...
Centre Hospitalier Et Universitaire De Limoges
Department of Clinical Hematology and Cell Therapy
Isle, France
Hopital Saint Louis
Department of Immuno-Hematology
Quinze-Vingts, France
Universitaetsklinikum Essen AöR
Dept. of Hematology and Stem Cell Tranplanatation
Essen, Germany
Sponsor: European Myeloma Network B.V.
Last updated: Nov 26, 2025
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.